AFFYMETRIX-WICHTIG - 500 Beiträge pro Seite

[germane]

Affymetrix, Inc. (the "Company") relies on sequence information that is in the
public domain for the design of its standard GeneChip probe arrays. The Company
has and plans to continue to invest substantial resources to ensure the accuracy
of this sequence information prior to the commercial release of its products.
The Company believes its recent acquisition of Neomorphic, Inc., a privately
held bioinformatics company, will further enable it to refine and ensure the
accuracy of the public domain sequence databases. Despite these efforts, because
of the rapidly evolving nature of the public domain sequence databases, sequence
errors may not be found prior to the commercial release of a product. The
magnitude and importance of these errors depends on multiple and complex factors
that the Company considers in determining appropriate actions to meet customer
needs. There can be no assurance that these actions will not have a material
adverse impact on the Company`s business, results of operations and financial
condition.

The Company has recently discovered errors in the UniGene U74 database build
that was used in the design of the Murine Genome U74 Set of GeneChip arrays. As
a result, the Company has begun the redesign of these arrays and has initiated
discussions with its affected customers to address their individual needs. Based
on these discussions, the Company is planning to offer certain replacement
arrays to these customers. The Company is currently evaluating the financial
impact of providing these replacement arrays and estimates preliminarily that
the total cost of this decision could be up to $4 million. Pending the outcome
of this analysis, the Company may be required to take additional product
warranty accruals in the quarter ended December 31, 2000 and/or in the current
fiscal quarter. In addition, sales of the Murine Genome U74 set of arrays may be
impacted.

All statements in this current report that are not historical are
"forward-looking statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding the Company`s
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause actual
results to differ materially for the Company from those projected, including,
but not limited to, uncertainties relating to technological approaches, product
development, manufacturing, market acceptance, personnel retention, equity
dilution, uncertainties related to the ability to realize benefits from
acquisitions, uncertainties related to cost and pricing of the Company`s
products, dependence on collaborative partners, uncertainties relating to sole
source suppliers, uncertainties relating to FDA and other regulatory approvals,
competition, risks relating to intellectual property of others and the
uncertainties of patent protection and litigation. These and other risk factors
are discussed in the Company`s Annual Report on Form 10-K for the year ended
December 31, 1999 and other SEC reports, including its Quarterly Reports on Form
10-Q for subsequent quarterly periods. The Company expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in the
Company`s expectations with regard thereto or any change in events, conditions,
or circumstances on which any such statements are based."

[germane]

Vorbörslich bei Island.com Heftiger Absturz

[germane]

Ob man AFFX danach kaufen sollte ?
Die werden wohl heute voll Abschmieren

[germane]

250 000 Stück gehandelt Vorbörslich 7% Minus